Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Megason Biotechnology

Request full access

Engineered migrasome technology for targeted drug delivery

ChinaFounded 2022

About Beijing Megason Biotechnology

Beijing Megason Biotechnology is a company at the forefront of harnessing migrasome biology for therapeutic applications. The company’s core technology revolves around migrasomes, which are large vesicular organelles discovered by Professor Li Yu's research group at Tsinghua University in 2014. These structures are formed during cell migration and play a crucial role in cell-to-cell communication by carrying and releasing signaling molecules like chemokines and cytokines to specific locations.

The company, also known as Migrasome Therapeutics Ltd., is leveraging the natural properties of migrasomes to develop an engineered drug delivery platform. This platform technology aims to overcome challenges faced by current biological delivery systems by offering a method with potentially high biocompatibility, low toxicity, and significant capacity for various drug types. The technology is designed for high modifiability, allowing both internal and external components of the migrasomes to be altered to carry different therapeutic agents. This adaptability is a key feature, enabling the potential for targeted, safe, and efficient delivery of multiple drugs to treat a range of diseases.

The scientific foundation of the company is built upon the extensive research of Professor Li Yu, who first identified these organelles and the process of their formation, termed migracytosis. Migrasomes function as natural packets of information, integrating spatial and temporal signals essential for processes like embryonic development and immune responses. Beijing Megason Biotechnology seeks to translate this fundamental biological discovery into innovative drug delivery systems and novel methods for disease diagnosis and treatment. The company's business model appears to be centered on the research and development of its proprietary migrasome-based platform, with a focus on addressing unmet medical needs through partnerships and the development of its own therapeutic pipeline.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
13.7/100
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jul 2023 $14M $55M Zhongguancun Development Group · Shoudu Keji Fazhan Jituan · Zhongguancun Collaborative Innovation Fund · Tsinghua Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Megason Biotechnology website traffic

Latest recorded traffic for Beijing Megason Biotechnology is 570 monthly website visits, up 18.8% over the last three months.

Latest monthly visits570 3-month web change+18.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Megason Biotechnology in its local ecosystem

Live from Dealroom

The Beijing Megason Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Zhongguancun Development Group
  • Shoudu Keji Fazhan Jituan
  • Zhongguancun Collaborative Innovation Fund
  • Tsinghua Capital
  • Qingjiu Technology
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Megason Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Megason Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.